Advertisement
Advertisement

AARD

AARD logo

Aardvark Therapeutics, Inc. Common Stock

12.99
USD
Sponsored
-0.36
-2.73%
Jan 30, 16:00 UTC -5
Closed
exchange

Pre-Market

12.99

0.00
+0.04%

AARD Earnings Reports

Positive Surprise Ratio

AARD beat 1 of 3 last estimates.

33%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.85
Implied change from Q3 25 (Revenue/ EPS)
--
/
+13.33%
Implied change from Q4 24 (Revenue/ EPS)
--
/
--

Aardvark Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, AARD reported earnings of -0.75 USD per share (EPS) for Q3 25, beating the estimate of -0.81 USD, resulting in a 7.92% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.85 USD, with revenue projected to reach -- USD, implying an increase of 13.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Aardvark Therapeutics, Inc. Common Stock reported EPS of -$0.75, beating estimates by 7.92%, and revenue of $0.00, 0% as expectations.
The stock price moved down -8.66%, changed from $10.86 before the earnings release to $9.92 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 12 analysts, Aardvark Therapeutics, Inc. Common Stock is expected to report EPS of -$0.85 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement